Abstract 3969: TP-0903, a potent AXL receptor tyrosine kinase inhibitor, enhances the activity of anti-PD-1 therapy in a metastatic preclinical syngeneic model of breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-3969
Abstract: The high rate of non-responders to immune checkpoint inhibitors (ICI) represents significant challenges in the field of immune-oncology. Breast cancer has emerged as a cancer type that responds poorly to ICI. Therefore, there is an… read more here.
Keywords: syngeneic model; 0903 potent; cancer; breast cancer ... See more keywords